Molecular Detection said today that life sciences and diagnostics distributor Eldan, part of the Neopharm Group, will exclusively distribute MDI's Detect-Ready MRSA Panel in Israel and the Palestinian territories.
Detect-Ready MRSA is a qualitative real-time PCR in vitro diagnostic test marketed in the European Union and Australia and in late-stage development in the US.
The test is CE-Marked for the detection of methicillin-resistant Staphylococcus aureus and methicillin-sensitive S. aureus, and the company claims that it is the only marketed PCR-based test able to accurately discriminate between the pathogen strains.
MDI said that the test is currently available in the UK, Germany, Ireland, Switzerland, Spain, Austria, Australia, the Netherlands, Belgium, and Luxembourg.
Last week, MDI said that it received a notice of allowance from the US Patent and Trademark Office for a patent covering a key aspect of Detect-Ready MRSA (PCR Insider, 7/14/2011).